Document:

EXHIBIT 10.11
​
​
FIRST MODIFICATION
TO THE
AMC ENTERTAINMENT HOLDINGS, INC.
2013 EQUITY INCENTIVE PLAN
Special Performance Stock Unit Awards Notice & Agreement
Dated February 26, 2020
First Modification Effective October 30, 2020
The Special Performance Stock Unit Award Notice and Agreement dated February 26, 2020 between AMC Entertainment Holdings, Inc. and Participant (the “Agreement”) is hereby modified as follows effective October 30, 2020.  Capitalized terms not defined herein shall have the same meaning as in the Agreement.
	section 1.	Participant’s base salary, annual incentive opportunity at target, and eligibility for future annual PSU and RSU grants under the EIP shall be restored to their pre-reduced levels effective October 30, 2020. 

	section 2.	The Stock Price Thresholds and Service Requirement for Tranches 1 through 4 of the SPSUs are hereby eliminated and such SPSUs shall vest on October 30, 2020.  Participant shall be prohibited from selling the shares of Common Stock issued upon the foregoing vesting until October 30, 2021.

	section 3.	The Stock Price Threshold for Tranche 5 of the SPSUs shall be changed to $4 and the Stock Price Threshold for Tranche 6 of the SPSUs shall be changed to $8.  The Service Requirement for Tranches 5 and 6 shall be shortened to end on October 30, 2021.

Except as set forth above, all provisions of the Agreement shall remain unaffected by this First Modification.EXHIBIT
10.1

 

AMENDMENT
TO EXCLUSIVE LICENSE AGREEMENT

 

THIS
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (“Amendment Agreement”) is made and entered into as
of October 30, 2020, by and between Inmune Ventures, LLC, a limited liability corporation organized and existing under the laws
of the State of Washington, having an office and its principal place of business at 1001 4th Avenue, Suite 4500 Seattle,
Washington 98154 (“Licenser”) and INmune Bio, Inc. a corporation organized and existing under the laws of the State
of Nevada, having an office and its principal place of business at 1224 Prospect Street, Suite 150, La Jolla, California 92037
(“Licensee”);

 

RECITALS

 

WEHREAS,
Licensor and Licensee entered into an Exclusive License Agreement on October 29, 2015 (the “License Agreement”)

 

WHEREAS,
Licensor and Licensee wish to amend Section 6.2 to the License Agreement to extend the dates of that the milestones need to be
achieved;

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

 

Section
1 Terms used but not defined. Terms used but not defined herein shall have the respective meanings given them in the Amendment
Agreement.

 

Section
2. Amendment to Section 6.2 of the License Agreement. Section 6.2 is hereby amended and restated in its entirety to
read as follows:

 

6.
2 In partial satisfaction of the obligations of Paragraph 6.1 above, LICENSEE shall achieve the following events within the time
frame set forth below:

 

	 	●	Filing of IND or
    equivalent:
	 	 	60
    months from Effective Date
	 	 	 
	 	●	Initiation of Phase
    I clinical trials or equivalent:
	 	 	72
    months from Effective Date
	 	 	 
	 	●	Initiation of Phase
    II clinical trials or equivalent:
	 	 	96
    months from successful completion of Phase I
	 	 	 
	 	●	Initiation of Phase
    III clinical trials or equivalent:
	 	 	120
    months from successful completion of Phase II
	 	 	 
	 	●	Filing of NDA or
    equivalent:
	 	 	132
    months from successful completion of Phase III

 

If
LICENSEE fails to achieve any of the development events set forth in this Article 6, and LICENSOR so notifies LICENSEE in writing,
LICENSEE and LICENSOR will negotiate in good faith to determine how LICENSEE can either remedy such failure or achieve alternate
development events. If LICENSEE fails to make any required efforts, after they are so determined, and does not remedy that failure
within sixty (60) days of written notice by LICENSOR, then LICENSOR may, by written notice to LICENSEE, terminate this License
or convert it to non-exclusive, at LICENSOR’S sole discretion.

 

     1

     

    

 

Section 3. Entire
Agreement. This Amendment Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties with respect to the subject
matter hereof. Except as amended by this Amendment Agreement, the Amendment Agreement shall continue in full force and effect.

 

Section 4. Severability.
If any term or other provision of this Amendment Agreement is invalid, illegal or incapable of being enforced by any Law or public
policy, all other terms and provisions of this Amendment Agreement shall nevertheless remain in full force and effect so long as
the economic or legal substance of the transactions contemplated by this Amendment Agreement is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced,
the parties hereto shall negotiate in good faith to modify this Amendment Agreement so as to effect the original intent of the
parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Amendment Agreement
are consummated as originally contemplated to the greatest extent possible.

 

 Section 5. Counterparts.
This Amendment Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by
the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of
which taken together shall constitute one and the same agreement.

 

Section 6. Dispute
Resolution. LICENSOR and LICENSEE shall attempt to settle between them amicably any controversy arising out of or related to
this Amendment Agreement or the breach thereof. A senior executive from each party shall consult and negotiate to reach a solution.
The Parties agree that the period of amicable resolution shall toll any otherwise applicable statute of limitations. However, nothing
in this clause shall preclude any party from commencing mediation if said negotiations do not result in a signed written settlement
agreement within thirty (30) days after written notice that these amicable resolution negotiations have commenced. In the event
the applicable statute of limitations shall expire prior to the expiration of the thirty (30) day period set forth in this section,
either party may commence an action as set forth in this Section. If said controversy cannot be settled according to this Section,
the Parties agree to good faith efforts to settle the controversy by mediation. The Party seeking mediation shall propose five
mediators, each of whom shall be a lawyer licensed to practice by the State of California, having practiced actively in the field
of commercial law for at least fifteen (15) years, to the other Party who shall select the mediator from the list. The Parties
shall split the cost of the mediator equally. The Parties agree that the period of mediation shall toll any otherwise applicable
statute of limitations. However, nothing in this clause shall preclude any Party from commencing further action if said mediation
does not result in a signed written settlement agreement within sixty (60) days after written notice that amicable resolution negotiations
have commenced. In the event the applicable statute of limitations shall expire prior to the expiration of the sixty (60) day period
set forth in this section, either party may commence an action as set forth in Section 6 of this Agreement.

  

Section 6 Court Venue.
If the Parties cannot reach agreement pursuant to this Section, then any dispute, controversy, or claim arising out of or relating
to this Agreement, or the breach, termination or invalidity thereof shall be finally settled judicially by a court of competent
jurisdiction in San Diego, California.

 

[Signature
Page Follows]

 

     2

     

    

 

IN
WITNESS WHEREOF, this Amendment Agreement has been duly executed by the parties hereto as of the day and year first above
written.

 

	 	IMMUNE
                    VENTURES, LLC 

        (Licensor)

	 	 	 
	 	By:	 
	 	 	David
        Moss

        Managing
        Member

	 	 	 
	 	 	 
	 	INMUNE BIO, INC. 

    (Licensee)
	 	 	 
	 	By:	 

  

[Signature
Page to the Amendment Agreement]

 

     3ttoo-ex101_246.htm

 

Exhibit 10.1

 

	
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	
 
	
1. CONTRACT ID CODE
	
 
	
PAGE OF PAGES

	
 
	
 
	
 
	
 
	
1
	
9

	
2. AMENDMENT/MODIFICATION NO.
	
3. EFFECTIVE DATE
	
4. REQUISITION/PURCHASE REQ. NO.
	
5. PROJECT NO. (If applicable)

	
P00002

6. ISSUED BY
	
09/25/2020
	
OS257167
	
 
	
 

	
 
	
CODE
	
ASPR-BARDA
	
7. ADMINISTERED BY (If other than Item 6)
	
CODE
	
ASPR-BARDA

	
 
	
 
	
 
	
 
	
 

	
ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

AUT

Washington DC 20201
	
ASPR-BARDA

US DEPT OF HEALTH & HUMAN SERVICES

BIOMEDICAL ADVANCED RESEACH & DEVELOPMENT

 

200 INDEPENDENCE AVE, S.W.

Washington DC 20201

 

 

	
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
	
(x)
	
9A. AMENDMENT OF SOLICITATION NO.
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
T2 BIOSYSTEMS, INC. 1512719 Attn: STEPHEN HAGAN
	
 
	
 
	
9B. DATED (SEE ITEM 11)
	
 
	
 

	
 
	
 
	
 
	
 

	
T2 BIOSYSTEMS, INC.

101 HARTWELL AVE LEXINGTON MA 024213125
	
 
	
x
	
10A. MODIFICATION OF CONTRACT/ORDER NO. 

 

75A50119C00053

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
10B. DATED (SEE ITEM 13)
	
 
	
 

	
CODE
	
1512719
	
FACILITY CODE
	
 
	
 
	
09/30/2019
	
 
	
 

	
11.  THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	
☐The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers
	
 
	
☐is extended
	
☐is not extended

	
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning                         copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	
12.  ACCOUNTING AND APPROPRIATION DATA (If required)
	
 
	
Net Increase:
	
$10,495,783.00

	
 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

 

	
2020.1992020.25106

	
13.  THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

 

	
CHECK ONE
	
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	
 

	
 
	
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	
 
	
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

	
X
	
D. OTHER (Specify type of modification and authority)

 

FAR 52.217-9 Option to Extend the Term of the Contract

 

	
E. IMPORTANT:
	
Contractor
	
☐is not
	
x is required to sign this document and return
	
1
	
 
	
☐copies to the issuing office.

	
 
	
 
	
 
	
 
	
 

	
14.  DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number: 20-4827488 

DUNS Number: 803126320

The purpose of this modification is to exercise and fully fund Option One (1).In addition, this modification will modify the following Articles: B.2 Base Period; B.3 Option Periods; B.4 Estimated Cost-Cost Sharing; B.6 Advance Understandings; G.3 Key Personnel; F.1 Estimated Period of Performance; and F.2 Deliverables; as well as update Section J with Attachment #1 - Statement of Work, dated September 12, 2020.

 

The Base period of performance end date remains as October 8, 2020 [UNCHANGED].

 

The Option 1 period of performance will be from [***]

 

Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect .

	
15A.NAME AND TITLE OF SIGNER (Type or print)
	
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

	
 
	
 

	
ALEC BARCLAY
	
ROSHAWN K. MAJORS

	
 
	
 
	
 
	
 

	
15B. CONTRACTOR/OFFEROR
	
15C. DATE SIGNED
	
16B. UNITED STATES OF AMERICA
	
16C. DATE SIGNED

	
 
	
/S/  ALEC BARCLAY
	
 
	
9/25/2020
	
 
	
 
	
 
	
 

	
(Signature of person authorized to sign)
	
 
	
(Signature of Contracting Officer)
	
 

	
 
	
 
	
 

	
Previous edition unusable
	
 
	
STANDARD FORM 30 (REV. 11/2016)

	
 
	
 
	
Prescribed by GSA FAR (48 CFR) 53.243

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

 

	
CONTINUATION SHEET
	
REFERENCE NO. OF DOCUMENT BEING CONTINUED
	
PAGE      OF

	
75A50119C00053/P00002
	
2
	
9

 

NAME OF OFFEROR OR CONTRACTOR

T2 BIOSYSTEMS, INC. 1512719

 

	
ITEM NO.
	
SUPPLIES/SERVICES
	
QUANTITY
	
UNIT
	
UNIT PRICE
	
AMOUNT

	
(A)
	
(B)
	
(C)
	
(D)
	
(E)
	
(F)

	
 
	
Appr. Yr.: 2020 CAN: 1992020 Object Class: 25106 Period of Performance: [***]

 
	
 
	
 
	
 
	
 

	
 
	
Change Item 2 to read as follows(amount shown is the oblied amount):

 
	
 
	
 
	
 
	
 

	
2
	
Option 1 Period:

[***]
	
 
	
 
	
 
	
10,495,783.00

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
NSN 7540-01-152-8067
	
 
	
OPTIONAL FORM 336 (4-86)

	
 
	
 
	
Sponsored by GSA 

	
 
	
 
	
FAR (48 CFR) 53.110

 

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

SUPPLEMENTAL AGREEMENT

 

**RED BOLD font denotes applicable changes

 

Beginning with the effective date of this modification, the Government and the Contractor mutually agree as follows: 

 

Under SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS, ARTICLE B.2 is hereby modified to reflect the following:

 

B.2 BASE PERIOD

 

	
 
	
1.
	
For the Government, the total estimated cost of the base period of this contract, excluding fee, is $5,978,993.  For the Contractor, the total estimated cost of the base period of this contract, excluding fee, is $[***]

 

	
 
	
2.
	
The Contractor shall maintain records of all contract costs and such records shall be subject to FAR 52.215-2 (Oct 2010), Audit and Records – Negotiation and incorporated by reference into the contract in SECTION I.

 

	
 
	
3.
	
The amount currently obligated will cover base performance of the contract through October 8, 2020.

 

	
CLIN
	
Period of Performance
	
Supplies/Services
	
BARDA Estimated Not To Exceed
	
T2 Estimated Not to Exceed
	
Overall Total Estimated Not to Exceed

	
0001
	
Base Period 9/9/2019

through

10/8/2020
	
[***]
	
$5,978,993
	
$[***]
	
$[***]

 

ARTICLE B.3 OPTION PERIODS - the table included in this Article is hereby modified to reflect the following:

 

B.3 COST REIMBURSMENT OPTIONS

 

	
 
	
a.
	
The contract includes optional, cost reimbursement CLINs 0002 through 0007.  The Government may exercise Option Periods in accordance with FAR 52.217-9 Option to Extend the Term of the Contract (March 2000), as set forth in Section I of the contract.   

 

	
 
	
b.
	
The contract includes optional services, cost reimbursement CLIN 0008.  The Government may exercise Option Services in accordance with FAR 52.217-8 Option to Extend Services, as set forth in Section I of the contract.   

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

	
 
	
c.
	
Unless the government exercises its option pursuant to the option clause contained in ARTICLE I.2, the contract consists only of the Base Work segment specified in the Statement of Work as defined in SECTONS C and F, for the price set forth in ARTICLE B.2 of the contract.

 

	
 
	
d.
	
The Government may modify the contract unilaterally and require the contractor to provide supplies and services for Option Periods listed below, in accordance with FAR 52.217-9.

 

	
 
	
e.
	
If the Government decides to exercise an option(s), the Government will provide the Contractor a preliminary written notice of its intent as referenced in the clause.  Specific information regarding the time frame for this notice is set forth in the OPTION CLAUSE Article in SECTION G of this contract. The estimated cost of the contract will be increased as set forth below:

 

							
	
Option
	
CLIN
	
Period of Performance
	
Supplies/Services
	
BARDA Estimated Not to Exceed
	
T2 Estimated Not to Exceed
	
Overall Total Estimated Not to Exceed

	
1
	
0002
	
[***]
	
Option 1 Period:

[***]
	
$10,495,783
	
$[***]
	
$[***]

	
2
	
0003
	
[***]
	
Option 2 Period:

[***]
	
$[***]
	
$[***]
	
$[***]

	
3
	
0004
	
[***]
	
Option 3 Period:

 

[***]
	
$[***]
	
$[***]
	
$[***]

	
4
	
0005
	
[***]
	
Option 4 Period:

 

[***]
	
$[***]
	
$[***]
	
$[***]

	
5
	
0006
	
[***]
	
Option 5 Period:

 

[***]
	
$[***]
	
$[***]
	
$[***]

	
6
	
007
	
[***]
	
Option 6 Period:
	
$[***]
	
$[***]
	
$[***]

	
Optional Services
	
0008
	
[***]
	
[***]
	
$[***]
	
$[***]
	
$[***]

	
 
	
 
	
TOTALS
	
Only option years
	
$[***]
	
$[***]
	
$[***]

	
 
	
 
	
TOTALS
	
Base + options
	
$68,952,025
	
$[***]
	
$[***]

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

ARTICLE B.4 ESTIMATED COST-COST SHARING is hereby modified as follows:  

B.4 ESTIMATED COST - COST SHARING

 

This is a cost-sharing contract. The overall estimated total cost sharing for performance under this contract is $[***] (Base plus Options for both BARDA and T2).  For further provisions regarding the specific cost-sharing arrangement, see the ADVANCE UNDERSTANDINGS, Article in SECTION B of the Contract.B.6. ADVANCE UNDERSTANDINGS, subparagraph (i), number (2) is hereby modified to reflect the following:

 

B.6 ADVANCE UNDERSTANDINGS

 

	
 
	
i.
	
Cost Sharing

	
 
	
2.
	
The Government shall provide monies in an amount not to exceed the values set forth Article B.2 and B.3.  The Contractor's share is estimated using the values set forth in Article B2. and B.3.

 

All other contract terms under Section B remains unchanged.

 

Under SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT, Statement of Work is hereby modified to reflect Attachment # 1 dated September 12, 2020 in Section J of this contract.

 

All other contract terms under Section C remains unchanged.

 

Under SECTION SECTION F – DELIVERIES OR PERFORMANCE, ARTICLES G.3 KEY PERSONNEL is hereby modified to reflect the following:

 

F.1 ESTIMATED PERIOD OF PERFORMANCE

 

The estimated period of performance for this contract shall be consistent with the dates set forth in the Base Period in Section B.2. If the Government exercises the Options Period(s) and/or Option Services, pursuant to the Option Clause in Section I.3 of the contract, the period of performance shall be increased as shown in the table in Section B.3.

 

F. 2 DELIVERABLES

 

Successful performance of the final contract shall be deemed to occur upon completion of performance of the work set forth in the Statement of Work dated September 12, 2020, set forth in Section J - List of Attachments of this contract and upon delivery and acceptance, as required by the Statement of Work, by the COR, of each of the deliverables described in Section C, Section F, and Section J.

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

All other contract terms under Section F remains unchanged.

 

Under SECTION G – CONTRACT ADMINISTRATION DATA, ARTICLE G.3 KEY PERSONNEL is hereby modified to reflect the following:

 

G.3 KEY PERSONNEL

 

Pursuant to the Key Personnel clause incorporated in Section I of this contract, the following individuals are considered to be essential to the work being performed hereunder:

 

	
Name
	
Title

	
Alec Barclay
	
Principal Investigator, Chief Operations Officer

	
Catherine Hogan
	
Director, Program Management

 

The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) and qualifications of the individual proposed as a substitute to permit evaluation by the Government of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the contractor or Government. At a minimum, the key personnel should include the project manager, principal investigator, radiation biologist, quality control manager, quality assurance director, regulatory lead, and manufacturing lead.

 

All other contract terms under Section G remains unchanged.

 

Under SECTION J LIST OF ATTACHMENTS is hereby modified to reflect the following:

 

	
 
	
1.
	
STATEMENT OF WORK

 

Statement of Work, dated September 12, 2020, 28 pages

 

All other contract terms under Section J remains unchanged.

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

CONTRACTOR’S STATEMENT OF RELEASE

 

In consideration of the modification(s) agreed to herein as complete and equitable adjustments of any sort are NOT due from Contractor's revision of Section J, Attachment 1 – Statement of Work, dated September 12, 2020.  The Contractor hereby releases the Government from any and all liability under the contract for further equitable adjustments attributable to such facts or circumstances as a result of this action.

 

All other contract terms remain unchanged.

 

 

END OF MODIFICATION P00002

 

 

 

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

	
 
	
 
	
 

	
Contract No: 75A50119C00053

Modification No: P0002
	
SPECIAL PROVISIONS
	
 

	
 
	
 
	
 

 

 

ATTACHMENT 1

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

(Solicitation   #BAA-18-100-SOL-00003)

Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

RAPID, HIGH-THROUGHPUT, MULTIPLEXED DETECTION OF BIOTHREAT SPECIES ID AND RESISTANCE GENES USING T2MR

Topic Area of Interest No. [7.2.4 & 7.3.3] Statement of Work DATED July 22, 2019 (Diagnostics/Devices Product Development)

 

STATEMENT OF WORK

 

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) BROAD AGENCY ANNOUNCEMENT (BAA) BAA-18-100-SOL-00003

 

ADVANCED RESEARCH AND DEVELOPMENT OF CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR MEDICAL COUNTERMEASURES

 

RAPID, HIGH-THROUGHPUT, MULTIPLEXED DETECTION OF BIOTHREAT SPECIES ID AND RESISTANCE GENES USING T2MR

AREA OF INTEREST NUMBERS 7.2.4 AND 7.3.3 CONTRACTUAL STATEMENT OF WORK

 

[***]

 

 

	
	
 

 

 

 

 

 

 

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]